10 free, board-style Neurology questions for the PANRE, each with the correct answer and a complete explanation. No email, no account required.
Neurology is 5% of the PANRE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.
Question 1NeurologyMedium
A 68-year-old man with a 6-year history of Parkinson's disease treated with carbidopa-levodopa develops new visual hallucinations and paranoid delusions. His motor symptoms remain well controlled, and reducing dopaminergic medications and reviewing his other drugs have not relieved the psychosis. Which of the following antipsychotic agents is the safest choice for this patient?
AOlanzapine
BHaloperidol
CRisperidone
DQuetiapine
EAripiprazole
Reveal answer & full explanation
Correct answer: D — Quetiapine
AOlanzapine
BHaloperidol
CRisperidone
DQuetiapine✓
EAripiprazole
Why Quetiapine is correct
Psychosis in Parkinson's disease requires an antipsychotic that does not block striatal dopamine and worsen motor function
Quetiapine has very low D2 affinity and is the practical first choice because it does not require the hematologic monitoring that clozapine does
It controls hallucinations and delusions while preserving the motor benefit of carbidopa-levodopa
Clozapine and pimavanserin are the other agents considered safe in Parkinson's disease psychosis
Why the others are wrong
Olanzapine — has meaningful D2 blockade and worsens parkinsonism (confused-with-a-safe-atypical)
Risperidone — a potent D2 antagonist that reliably aggravates motor symptoms (confused-with-a-safe-atypical)
Haloperidol — a typical antipsychotic with strong dopamine blockade that markedly worsens parkinsonism (anchoring on a familiar antipsychotic)
Aripiprazole — a D2 partial agonist, which makes it sound dopamine-sparing, but in Parkinson's disease psychosis it has worsened motor function and been poorly tolerated, so it is not among the agents considered safe (mistaking partial agonism for motor safety)
Question 2NeurologyMedium
A 29-year-old woman with migraine without aura started topiramate for prophylaxis 11 days ago and increased the dose 3 days ago. She now has 1 day of bilateral eye pain, frontal headache, and blurred distance vision, although near print has become easier to read than before. Both eyes are diffusely injected with hazy corneas and mid-dilated, sluggish pupils. Visual acuity is 20/80 in each eye, and intraocular pressure is 44 mm Hg on the right and 41 mm Hg on the left. Refraction documents a new 3-diopter myopic shift in both eyes, and the anterior chambers are shallow bilaterally. Which of the following is the most appropriate next step in management?
AStop topiramate and recheck vision and intraocular pressure in 1 week
BStop topiramate and start pressure-lowering drops and cycloplegic atropine
CContinue topiramate and start hourly topical pilocarpine drops in both eyes
DReduce the topiramate dose and add a pressure-lowering beta-blocker drop
EStop topiramate and arrange urgent bilateral laser peripheral iridotomies
Reveal answer & full explanation
Correct answer: B — Stop topiramate and start pressure-lowering drops and cycloplegic atropine
AStop topiramate and recheck vision and intraocular pressure in 1 week
BStop topiramate and start pressure-lowering drops and cycloplegic atropine✓
CContinue topiramate and start hourly topical pilocarpine drops in both eyes
DReduce the topiramate dose and add a pressure-lowering beta-blocker drop
EStop topiramate and arrange urgent bilateral laser peripheral iridotomies
Why Stop topiramate and start pressure-lowering drops and cycloplegic atropine is correct
Topiramate, a sulfamate-substituted monosaccharide, triggers an idiosyncratic ciliochoroidal effusion within days to about 2 weeks of starting or escalating the drug; the swollen ciliary body rotates forward, slackens the zonules, and pushes the lens-iris diaphragm anteriorly so that both angles close at once
Forward movement and thickening of the lens also increase the eye's refractive power, producing the acute myopic shift that blurs distance vision while near print sharpens - the fingerprint that separates this reaction from primary angle closure
The reaction is idiosyncratic rather than dose-proportional, so it can follow a first dose or a dose increase, and it will not settle while the drug is on board; stopping topiramate is the definitive step but not a sufficient one, because the shut angle and the pressure still have to be treated today
A pressure in the 40s injures the optic nerve within hours, so the same visit lowers it with aqueous suppressants - a topical beta-blocker, a topical alpha-2 agonist, and a topical or systemic carbonic anhydrase inhibitor - reserving a hyperosmotic agent such as mannitol, which works by a different route and pulls water osmotically out of the vitreous, for a pressure that does not fall
Cycloplegia with atropine is the half aimed at the mechanism: it rotates the ciliary body back, tightens the zonules, and lets the lens-iris diaphragm fall back so the angle reopens
Bilateral simultaneous closure in a 29-year-old is the tell: primary angle closure is typically a unilateral event in older hyperopes, so a drug started 11 days ago owns this presentation until proven otherwise
Why the others are wrong
Stop topiramate and arrange urgent bilateral laser peripheral iridotomies - withdrawal is right and the urgency is right, but the laser is the wrong second half: an iridotomy helps only when aqueous is trapped behind the iris by pupillary block, and there is no pupillary block here - a swollen ciliary body has pushed the whole lens-iris diaphragm forward, so the angle stays shut after the openings are made (the trap is running the primary angle-closure algorithm on a secondary mechanism)
Continue topiramate and start hourly topical pilocarpine drops in both eyes - both halves are wrong: the effusion will not settle while the drug is on board, and pilocarpine is the reflex miotic from primary angle closure that contracts the ciliary muscle, slackens the zonules, and lets the lens sit still further forward, which can deepen this closure. Cycloplegia, not miosis, reverses the mechanism (the trap is reaching for the drug that works when the problem is pupillary block)
Reduce the topiramate dose and add a pressure-lowering beta-blocker drop - a beta-blocker is a legitimate part of pressure lowering, but the reaction is idiosyncratic rather than dose-proportional, so a lower dose keeps the effusion going, and aqueous suppression without cycloplegia leaves the angle mechanically shut (the trap is treating an idiosyncratic reaction as though it were a dose-related side effect)
Stop topiramate and recheck vision and intraocular pressure in 1 week - withdrawal is the definitive step and most cases do settle within 1 to 2 weeks of stopping, which is why watchful waiting baits, but a pressure in the 40s with corneal edema and 20/80 acuity can injure the optic nerve within hours, so the pressure and the shut angle are treated today with aqueous suppressants and cycloplegia rather than left to the drug washout (the trap is treating withdrawal as sufficient on its own)
Additional high-yield points
Reassurance is the other tempting error: paresthesias, taste change, cognitive slowing, and painless blurring are the benign self-limited effects of topiramate, but acuity of 20/80 with corneal edema and a pressure above 40 mm Hg is a sight-threatening emergency that cannot be watched for a day
The same ciliochoroidal effusion syndrome is reported with other sulfonamide-derived drugs - hydrochlorothiazide, sulfamethoxazole, and zonisamide - so ask about every new prescription in any bilateral acute angle closure
Anticholinergic and sympathomimetic mydriasis can also precipitate angle closure, but that mechanism IS pupillary block in an anatomically narrow eye, and those eyes do respond to laser peripheral iridotomy
In primary acute angle closure the sequence is medical pressure lowering first, then definitive laser peripheral iridotomy of the affected eye plus a prophylactic iridotomy of the fellow eye
Most drug-induced cases settle within 1 to 2 weeks of stopping the drug; do not rechallenge, and switch prophylaxis to another class such as propranolol, candesartan, or a CGRP monoclonal antibody - zonisamide is a sulfonamide like topiramate, and amitriptyline is a poor choice after an angle-closure episode because its anticholinergic effect is itself a recognized precipitant
Topiramate's other counseling points for a young woman: nephrolithiasis, metabolic acidosis, weight loss, oligohidrosis with hyperthermia, and teratogenicity (oral clefts), so pregnancy status and contraception are addressed before it is started
Question 3NeurologyMedium
A 58-year-old woman develops symmetric weakness that begins in her proximal legs and ascends over 10 days. On examination she has flaccid weakness, absent deep tendon reflexes, and labile blood pressure and heart rate. Cerebrospinal fluid analysis shows protein 420 mg/dL with a white blood cell count of 6/mm³. Nerve conduction studies show markedly reduced conduction velocities. Which of the following is the most important parameter to monitor?
AContinuous pulse oximetry
BSerial serum sodium
CForced vital capacity
DSerial nerve conduction studies
ESerum creatine kinase
Reveal answer & full explanation
Correct answer: C — Forced vital capacity
AContinuous pulse oximetry
BSerial serum sodium
CForced vital capacity✓
DSerial nerve conduction studies
ESerum creatine kinase
Why Forced vital capacity is correct
The ascending flaccid weakness, areflexia, autonomic instability, albuminocytologic dissociation, and slowed conduction velocities indicate Guillain-Barré syndrome
The major life threat is neuromuscular respiratory failure, so serial forced vital capacity (with negative inspiratory force) guides the need for intubation
A falling FVC toward roughly 20 mL/kg signals impending respiratory failure before oxygen saturation drops
IVIG or plasmapheresis is the treatment; corticosteroids are ineffective
Why the others are wrong
Serum creatine kinase — tracks muscle breakdown in myopathies and has no role in monitoring respiratory status in a neuropathy (confused-with-a-myopathy)
Serial serum sodium — hyponatremia from SIADH is a real complication of Guillain-Barré syndrome and is worth following, but it is not the parameter that determines the need for intubation, so it is not the most important one here (real-but-lower-priority)
Serial nerve conduction studies — repeating a study already performed tracks the demyelinating lesion rather than ventilatory reserve, and the electrophysiologic changes lag the clinical course, so they cannot time airway protection (confused-with-tracking-the-lesion)
Continuous pulse oximetry — it watches the respiratory system, which is why it tempts, but in neuromuscular respiratory failure oxygen saturation is preserved until late, especially on supplemental oxygen, because hypoventilation and fatigue come first; a normal saturation gives false reassurance and cannot time intubation the way a falling FVC does (confused-with-hypoxemic-failure)
Question 4NeurologyMedium
A 65-year-old man with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) has had a fourth lacunar stroke in 3 years despite aspirin therapy. MRI of the brain shows extensive white matter lesions. Which of the following is the most appropriate management strategy?
ABlood pressure control plus antiplatelet
BEscalation to high-dose aspirin therapy
CDual antiplatelet with clopidogrel-aspirin
DWarfarin anticoagulation therapy
ELong-term nimodipine prophylaxis
Reveal answer & full explanation
Correct answer: A — Blood pressure control plus antiplatelet
ABlood pressure control plus antiplatelet✓
BEscalation to high-dose aspirin therapy
CDual antiplatelet with clopidogrel-aspirin
DWarfarin anticoagulation therapy
ELong-term nimodipine prophylaxis
Why blood pressure control plus antiplatelet is correct
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is caused by a NOTCH3 mutation and is a hereditary small vessel disease causing recurrent lacunar strokes and subcortical dementia.
The cornerstone of management is aggressive blood pressure control (target <130/80), which is the most important intervention.
Antiplatelet therapy (aspirin) and smoking cessation are also recommended.
Why the others are wrong
Dual antiplatelet with clopidogrel-aspirin — No proven benefit of dual antiplatelet therapy in CADASIL, and the microbleed burden raises hemorrhage risk; over-treatment trap.
Warfarin anticoagulation therapy — No proven benefit; anticoagulation is not standard of care in CADASIL and increases bleeding risk; confused-with-cardioembolic-stroke trap.
Long-term nimodipine prophylaxis — Nimodipine is a 21-day course after aneurysmal subarachnoid hemorrhage to limit delayed cerebral ischemia; it has no established role in CADASIL, does not prevent lacunar infarcts, and lacks the antiplatelet half of the correct strategy; right-drug-wrong-disease trap.
Escalation to high-dose aspirin therapy — recurrence despite aspirin invites the idea that the dose was too low, but trials comparing low and high aspirin doses show no added stroke protection at higher doses, only more gastrointestinal toxicity, and recurrent lacunes in CADASIL reflect progressive small vessel disease, where aggressive blood pressure control is the cornerstone; aspirin-failure-dose-escalation trap.
Additional high-yield points
Genetic counseling is recommended for family members given the autosomal dominant inheritance.
Prognosis involves progressive cognitive decline and disability.
Question 5NeurologyMedium
A 72-year-old man undergoing evaluation for severe aortic stenosis develops sudden bilateral leg weakness, urinary retention, and loss of pain and temperature sensation below the level of the umbilicus. Proprioception and vibration sense are preserved in both legs. MRI of the spine shows an anterior cord T2 signal change at the T9 level. In addition to treating the underlying cause, which of the following is the most appropriate management?
AEmergent surgical decompression
BIntravenous antihypertensive therapy
CTherapeutic anticoagulation
DHigh-dose intravenous corticosteroids
EMean arterial pressure augmentation
Reveal answer & full explanation
Correct answer: E — Mean arterial pressure augmentation
AEmergent surgical decompression
BIntravenous antihypertensive therapy
CTherapeutic anticoagulation
DHigh-dose intravenous corticosteroids
EMean arterial pressure augmentation✓
Why mean arterial pressure augmentation is correct
The presentation is anterior spinal cord syndrome caused by anterior spinal artery ischemia: motor paralysis, loss of pain and temperature sensation, and bladder dysfunction below the lesion, with preserved proprioception and vibration.
Proprioception and vibration are preserved because the dorsal columns are supplied by the separate posterior spinal arteries.
The anterior two-thirds of the cord is supplied by the anterior spinal artery and is injured by hypoperfusion.
Because the injury is ischemic, the cornerstone of management is augmenting spinal cord perfusion by targeting a mean arterial pressure above roughly 85–90 mm Hg and avoiding hypotension, alongside treatment of the underlying cause.
Anterior cord syndrome is classically associated with aortic disease, hypotension, and embolic events.
Why the others are wrong
Therapeutic anticoagulation — Not first-line; the mechanism is typically arterial hypoperfusion or embolism rather than a thrombus requiring systemic anticoagulation, and it carries bleeding risk without proven benefit.
High-dose intravenous corticosteroids — Tempting because students associate steroids with acute spinal cord injury, but they are not evidence-based for ischemic anterior cord syndrome and are not standard of care here.
Emergent surgical decompression — Indicated for compressive cord lesions such as epidural hematoma, abscess, or tumor; imaging here shows ischemic signal change without a compressive mass, so there is nothing to decompress.
Intravenous antihypertensive therapy — aortic disease brings to mind aortic dissection, where blood pressure and heart rate are lowered, but this cord injury is ischemic and depends on perfusion pressure; lowering blood pressure would deepen the ischemia, and the fixed outflow obstruction of severe aortic stenosis makes hypotension especially poorly tolerated.
Additional high-yield points
Anterior cord syndrome carries the worst prognosis of the incomplete cord syndromes, underscoring the importance of optimizing perfusion early.
Question 6NeurologyMedium
A 68-year-old female has a 3-month history of progressive cognitive decline, visual hallucinations, and Parkinson-like features (rigidity and bradykinesia) that preceded the dementia by 6 months. She is extremely sensitive to haloperidol, developing severe rigidity after a single dose. Which of the following is the most likely diagnosis?
AVascular dementia
BFrontotemporal dementia
CAlzheimer disease
DParkinson disease dementia
EDementia with Lewy bodies
Reveal answer & full explanation
Correct answer: E — Dementia with Lewy bodies
AVascular dementia
BFrontotemporal dementia
CAlzheimer disease
DParkinson disease dementia
EDementia with Lewy bodies✓
Why Dementia with Lewy bodies is correct
Core features of dementia with Lewy bodies (DLB): (1) fluctuating cognition, (2) recurrent complex and detailed visual hallucinations, (3) parkinsonism, (4) REM sleep behavior disorder
The timing distinguishes DLB from Parkinson disease dementia (PDD): DLB = dementia precedes or is concurrent with motor features (dementia within 1 year of parkinsonism); in this patient parkinsonism preceded dementia by only 6 months
Neuroleptic sensitivity (severe and potentially fatal worsening of parkinsonism and autonomic instability) is a hallmark; typical and most atypical antipsychotics are ABSOLUTELY CONTRAINDICATED
Why the others are wrong
Alzheimer disease — gradual memory-predominant decline; no parkinsonism, no visual hallucinations as early features; no neuroleptic sensitivity
Vascular dementia — stepwise decline, focal neurologic deficits, cerebrovascular disease on imaging; not associated with parkinsonism or neuroleptic sensitivity
Parkinson disease dementia — motor features precede dementia by more than 1 year; clinical overlap with DLB is real, but the 6-month interval here favors DLB by convention
Frontotemporal dementia — presents with early personality and behavioral change (disinhibition, apathy) or progressive language decline, typically with onset before 65; parkinsonism can accompany it, but recurrent visual hallucinations and severe neuroleptic sensitivity point to DLB
Additional high-yield points
Treatment: a cholinesterase inhibitor (rivastigmine or donepezil) for cognition and hallucinations; use in DLB is off-label in the US (rivastigmine is FDA-approved for Alzheimer and Parkinson disease dementia, not DLB)
Levodopa for motor features
Melatonin (preferred in DLB because clonazepam can worsen cognition and gait) or low-dose clonazepam for REM sleep behavior disorder (RBD)
Question 7NeurologyMedium
A 75-year-old woman comes to the emergency department 13 hours after the sudden onset of the worst headache of her life, which reached maximal intensity within seconds; she stayed home overnight hoping it would pass. She reports photophobia and has neck stiffness on examination; the neurologic examination is otherwise normal. A noncontrast head CT obtained on arrival shows no hemorrhage. Lumbar puncture is performed 14 hours after headache onset; it requires several needle passes, and the first tube of cerebrospinal fluid is blood-tinged. Which of the following findings would most reliably distinguish a traumatic tap from subarachnoid hemorrhage in this patient?
ACrenated red blood cells in the CSF
BXanthochromia of CSF
CVisible clotting of the CSF
DDecreasing RBC count from tube 1 to tube 4
EElevated CSF protein above 100 mg/dL
Reveal answer & full explanation
Correct answer: B — Xanthochromia of CSF
ACrenated red blood cells in the CSF
BXanthochromia of CSF✓
CVisible clotting of the CSF
DDecreasing RBC count from tube 1 to tube 4
EElevated CSF protein above 100 mg/dL
Why Xanthochromia of CSF is correct
Xanthochromia is yellow CSF supernatant from bilirubin, which forms in vivo over hours from the oxyhemoglobin that lysed RBCs release; blood introduced by the needle cannot form it before the sample is processed, so xanthochromia is the most specific CSF finding for telling true subarachnoid hemorrhage (SAH) from a traumatic tap.
It is reliably detectable from about 12 hours after onset (UK NEQAS 2008 advises lumbar puncture (LP) only >12 hours after onset) and persists for at least 2 weeks, so this LP at 14 hours can be interpreted: if she bled, bilirubin should already be present.
Spectrophotometry is the most sensitive method; visual inspection, common in North American labs, is highly specific but less sensitive (pooled sensitivity 71%; 47% in Perry 2015). ACEP 2019 notes that no method for separating the two, xanthochromia included, is agreed to be reliable: it is the best discriminator, not an infallible one.
Why the others are wrong
Visible clotting of the CSF — the classic bedside sign of a traumatic tap because the needle introduces peripheral fibrinogen, but clotting needs a heavily bloody sample, so a lightly blood-tinged traumatic tap usually does not clot and a missing clot cannot exclude one; ACEP 2019 lists clot formation among the methods not agreed to be reliable.
Decreasing RBC count from tube 1 to tube 4 — tube clearing is the widely taught bedside test, but counts show how much blood is in the tube, not how long it has been there, and a traumatic tap can occur on top of a true SAH, so a falling count is not a reliable rule-out unless the final tube is zero or near zero (ACEP 2019). In one retrospective series (Czuczman 2013) the simple initial-to-final-tube difference did not discriminate (area under the curve 0.45) and percent drop did better (0.84), but no cutoff has been validated, and Perry 2015 did not assess a safe drop.
Elevated CSF protein above 100 mg/dL — blood from any source raises CSF protein; in Perry 2015 the median was only modestly higher in SAH (56 vs 40 mg/dL, a gap the authors judged of doubtful clinical relevance), and both medians, like most SAH values, sit below this 100 mg/dL cutoff.
Crenated red blood cells in the CSF — once taught as a sign that blood had been in the CSF for hours, but red cells can crenate in either setting, including a traumatic tap, so crenation does not reliably separate the two, whereas xanthochromia reflects bilirubin formed in vivo.
Additional high-yield points
An LP is not needed after a normal noncontrast CT within 6 hours of onset in a patient with a normal neurologic exam, because that scan rules out nontraumatic SAH (ACEP 2019, Level B). A patient still at risk after a negative CT, as here, needs LP or CT angiography (CTA), chosen by shared decision making (ACEP 2019, Level C).
Perry 2015: no xanthochromia plus a final-tube RBC count below 2,000 x10^6/L excluded aneurysmal SAH (sensitivity 100%, 95% CI 74.7-100%; specificity 91.2%), but with only 15 SAH cases the interval is wide.
After a traumatic or uninterpretable tap, next tests include repeat LP at a different site, CTA, digital subtraction angiography, or MR angiography (ACEP 2019).
D-dimers in CSF may help distinguish traumatic tap from SAH but are not yet standardized.
Question 8NeurologyMedium
A 70-year-old man has slowly progressive forgetfulness, occasionally gets lost while driving, and needs help organizing his finances but remains independent in basic activities. His wife reports mild repetitive questioning. Mini-Mental State Examination (MMSE) is 23/30. MRI shows bilateral hippocampal atrophy and no microhemorrhages. CSF analysis shows low Abeta42, elevated total-tau, and elevated phospho-tau. Which of the following therapies is most likely to slow the underlying disease process?
ABrexpiprazole
BSolanezumab
CMemantine
DLecanemab
EDonepezil
Reveal answer & full explanation
Correct answer: D — Lecanemab
ABrexpiprazole
BSolanezumab
CMemantine
DLecanemab✓
EDonepezil
Why Lecanemab is correct
The picture is early Alzheimer disease (AD): amnestic decline with an MMSE of 23/30 (mild dementia range) plus a confirmatory CSF biomarker profile of low Abeta42 and elevated total-tau and phospho-tau
Lecanemab is an anti-amyloid-beta monoclonal antibody directed at soluble protofibrils and is FDA-approved for mild cognitive impairment or mild dementia due to AD with confirmed amyloid pathology
In the CLARITY-AD trial it slowed clinical decline by roughly 27% versus placebo over 18 months, making it disease-modifying rather than purely symptomatic
Eligibility requires confirmed amyloid pathology (CSF or amyloid PET) and a baseline MRI; donanemab is a similarly disease-modifying alternative
Why the others are wrong
Donepezil — a cholinesterase inhibitor that improves symptoms by raising synaptic acetylcholine but does not alter amyloid pathology or the disease trajectory (right-concept-wrong-mechanism)
Solanezumab — also an anti-amyloid monoclonal antibody, but it binds monomeric soluble Abeta rather than the protofibrils and deposited plaque that have to be cleared; it failed to slow decline in the EXPEDITION program and in the A4 trial and was never approved, so it does not modify the disease (right-class-wrong-target)
Memantine — an NMDA-receptor antagonist used in moderate-to-severe AD for symptom control, not to slow underlying pathology (anchoring on AD label without matching mechanism)
Brexpiprazole — an atypical antipsychotic that does carry an FDA indication in Alzheimer disease, but only for agitation associated with AD dementia; it does not affect amyloid or tau pathology, nothing in this vignette describes agitation, and antipsychotics carry a boxed warning for increased mortality in older adults with dementia-related psychosis (anchoring on an AD-specific approval)
Additional high-yield points
Amyloid-related imaging abnormalities (ARIA-E edema, ARIA-H microhemorrhage) require serial MRI monitoring during anti-amyloid therapy
APOE4 carriers (especially homozygotes) have higher ARIA risk, and concurrent anticoagulation raises ARIA-H/hemorrhage risk, so genotype and bleeding risk should be assessed before starting
Question 9NeurologyMedium
A 50-year-old male has a 6-month history of progressive left arm weakness, left leg spasticity, and dysphagia. Exam shows fasciculations in the left arm and tongue, hyperreflexia in the left leg, and a positive Hoffman sign. Which of the following tests best confirms the suspected diagnosis?
AElectromyography plus nerve conduction studies
BCerebrospinal fluid analysis with cytology
COpen muscle biopsy with immunohistochemistry
DGenetic testing for SOD1 and C9orf72 variants
EMRI of the brain and cervical spine
Reveal answer & full explanation
Correct answer: A — Electromyography plus nerve conduction studies
AElectromyography plus nerve conduction studies✓
BCerebrospinal fluid analysis with cytology
COpen muscle biopsy with immunohistochemistry
DGenetic testing for SOD1 and C9orf72 variants
EMRI of the brain and cervical spine
Why Electromyography plus nerve conduction studies is correct
Amyotrophic lateral sclerosis (ALS) is a clinical diagnosis based on El Escorial criteria: upper motor neuron (UMN) and lower motor neuron (LMN) signs in multiple regions (bulbar, cervical, thoracic, lumbar), progressive course, no sensory involvement, and no other explanatory diagnosis.
Electromyography (EMG) and nerve conduction studies (NCS) confirm widespread LMN involvement by showing fibrillation potentials, positive sharp waves, and reduced motor unit recruitment across multiple myotomes.
There is no definitive biomarker; ALS is a diagnosis of exclusion.
Why the others are wrong
Cerebrospinal fluid analysis with cytology — CSF studies are used to exclude inflammatory or infectious mimics, not to confirm the LMN denervation that defines ALS (confused-with mimic workup).
MRI of the brain and cervical spine — imaging excludes structural and compressive lesions but does not demonstrate the multilevel LMN denervation needed for diagnosis (rule-out-not-confirm).
Open muscle biopsy with immunohistochemistry — biopsy is reserved for suspected primary myopathy and does not establish a motor neuron disease diagnosis (right-concept-wrong-test).
Genetic testing for SOD1 and C9orf72 variants — now routinely offered after an ALS diagnosis because a SOD1 variant opens the door to tofersen, but most patients carry no identifiable pathogenic variant, so a negative panel cannot exclude ALS and testing does not demonstrate the multiregion LMN denervation needed to confirm the diagnosis (right-concept-wrong-purpose).
Additional high-yield points
Median survival is 3-5 years from symptom onset.
Prognostic factors: bulbar onset confers worse prognosis due to aspiration risk; older age at onset and rapid progression are also adverse factors.
Riluzole extends survival by 2-3 months.
Edaravone (IV/oral) reduces functional decline in selected patients.
AMX0035 (sodium phenylbutyrate-taurursodiol) was withdrawn from the US market in 2024 after its confirmatory trial failed.
Tofersen targets the superoxide dismutase 1 (SOD1) mutation and reduces the neurofilament light chain (NfL) biomarker.
Multidisciplinary care is essential.
Question 10NeurologyMedium
A 35-year-old female has a 2-year history of intermittent diplopia, worse with sustained upgaze, and bilateral ptosis that worsens throughout the day. She notices her voice becomes nasal after prolonged speaking. Ice pack test improves ptosis. Anti-acetylcholine receptor (anti-AChR) antibodies are positive. CT chest shows an anterior mediastinal mass. Which of the following is the most likely diagnosis?
ALambert-Eaton myasthenic syndrome
BAnti-MuSK myasthenia gravis
CThyroid eye disease
DOcular myasthenia gravis
EMyasthenia gravis with thymoma
Reveal answer & full explanation
Correct answer: E — Myasthenia gravis with thymoma
ALambert-Eaton myasthenic syndrome
BAnti-MuSK myasthenia gravis
CThyroid eye disease
DOcular myasthenia gravis
EMyasthenia gravis with thymoma✓
Why Myasthenia gravis with thymoma is correct
Anti-acetylcholine receptor (anti-AChR) antibodies are positive in 85% of generalized myasthenia gravis (MG).
Thymoma is identified in 10-15% of MG patients; an anterior mediastinal mass combined with AChR-positive MG indicates thymoma-associated MG.
Thymectomy is mandatory for thymoma (oncologic indication) and is also beneficial for non-thymomatous generalized MG in patients under 65 (MGTX trial).
Why the others are wrong
Ocular myasthenia gravis — ocular MG is limited to ocular symptoms; this patient also has bulbar involvement (nasal voice) and a thymoma, making generalized thymoma-associated MG the correct classification (premature closure).
Lambert-Eaton myasthenic syndrome — Lambert-Eaton causes proximal limb weakness that briefly improves with repeated activity (facilitation), not fatigable ocular/bulbar weakness with positive AChR antibody and thymoma (confused-with NMJ disorder).
Thyroid eye disease — thyroid orbitopathy produces lid retraction, proptosis, and restrictive diplopia from enlarged extraocular muscles rather than fatigable ptosis that improves with an ice pack, and it explains neither the AChR antibodies nor the anterior mediastinal mass (confused-with ocular diagnosis).
Anti-MuSK myasthenia gravis — muscle-specific kinase (MuSK) antibody MG is tempting because it is bulbar-predominant, matching the nasal voice, but it occurs almost exclusively in patients who are anti-AChR antibody negative and is not associated with thymoma, so positive anti-AChR antibodies and an anterior mediastinal mass point away from it (confused-with seronegative subtype).
Additional high-yield points
Symptomatic therapy: pyridostigmine.
Immunosuppression: prednisone plus azathioprine or mycophenolate.
Crisis management: intravenous immunoglobulin (IVIG) or plasmapheresis.
Refractory disease: eculizumab (REGAIN trial) or rozanolixizumab (anti-neonatal Fc receptor (anti-FcRn)).
That's 10 of 7,700+. Get the rest.
Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
Are these Neurology PANRE practice questions free?
Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.
How much of the PANRE is Neurology?
Neurology makes up 5% of the PANRE content blueprint. FirstPassPA's timed PANRE exams are dealt to the same weights, so a practice exam carries the same share of Neurology questions.
How should I use these questions?
Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Neurology questions in the app, or take a full timed PANRE practice exam dealt to the blueprint weights.
Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.